The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2022 | Bringing CTCs to the forefront of therapeutics
Scott Kopetz, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, describes important requirements for circulating tumor cells (CTCs) to move forward in the pharmaceutical industry. This includes uncovering which patients CTC approaches should be examined on and whether there are a subset of patients that are insensitive to CTC methods. Additionally, Dr. Kopetz mentions the need for understanding the regulatory framework in this therapeutic area as well as more innovative trail design. This interview took place at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium.
